Navigation Links
Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
Date:11/8/2012

NEW YORK, Nov. 8, 2012 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of DUSA Pharmaceuticals, Inc. ("DUSA" or the "Company") (NASDAQ: DUSA) concerning the proposed acquisition of the Company by Sun Pharmaceutical Industries Ltd. ("Sun Pharmaceuticals") in a transaction valued at approximately $230 million. 

(Logo:  http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )

On November 8, 2012, it was announced that DUSA and Sun Pharmaceuticals have entered into a definitive agreement pursuant to which Sun Pharmaceuticals will acquire DUSA.  Under the terms of the transaction, DUSA shareholders will receive $8.00 in cash per share held.  At least one analyst has set a target price for DUSA stock of $9.50 per share.

Our investigation concerns whether the DUSA board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders. 

If you own DUSA shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Benjamin Sachs-Michaels, Esq.

Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the H
'/>"/>

SOURCE Harwood Feffer LLP
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of PSS World Medical, Inc.
2. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
3. ActiveCare Announces Record Revenue For Quarter Ending June 30, 2012
4. Echo Therapeutics Announces Third Quarter 2012 Financial Results
5. Concord Medical Announces Change to Third Quarter Financial Results Date to November 20, 2012
6. Winner Medical Announces Mailing of Definitive Proxy Materials for Special Meeting of Shareholders
7. Genoa Pharmaceuticals announces $1.2M Financing
8. Genomic Health Announces Third Quarter 2012 Financial Results and Business Progress
9. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
10. Life Technologies Announces Next-Gen Digital PCR Instrument Designed for Widespread Adoption
11. Blue Belt Technologies Announces First United Kingdom-Based NavioPFS Unicondylar Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 Ranbaxy Laboratories ... Co., Ltd. (hereafter, Daiichi Sankyo), announced on May ... recent years to address past conduct under prior ... Daiichi Sankyo continues to support Ranbaxy ... conduct of the past which led to the ...
(Date:5/22/2013)... 22. Mai 2013  Grifols, ein globales ... Barcelona , Spanien, präsentierte die ... höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den ... (AAT) auf ein Niveau anhebt, das innerhalb ... liegt. ATT-Mangel ist eine lebensbedrohliche, genetische Erkrankung, ...
(Date:5/22/2013)... and REHOVOT, Israel , May 22, ... ), a leading developer and provider of microRNA-based molecular ... , President and Chief Executive Officer of Rosetta Genomics, ... Healthcare Conference taking place from June 3-6, 2013 in ... on Tuesday, June 4 th at 2:00 p.m. ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3
... N.J., Jan. 4, 2012   CANTEL MEDICAL CORP. ... CEO, will be presenting at the Needham & Company, ... scheduled for 9:20 AM ET on Wednesday, January 11, ... Q & A session immediately following the presentation. In ...
... marketers who need to calibrate multi-channel marketing and sales ... SyntheSight™ , a new proprietary pharmaceutical ... patent-pending IntelliScore™ , provides actionable insights ... answers. SyntheSight ...
Cached Medicine Technology:RMi Introduces SyntheSight™ Pharma Multi-Channel Optimization Suite 2RMi Introduces SyntheSight™ Pharma Multi-Channel Optimization Suite 3
(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Fish oil ... 2 diabetes, new research suggests. The ... levels of a hormone called adiponectin that,s linked ... of this hormone in the bloodstream have also ... disease. "While prior animal studies found fish ...
(Date:5/22/2013)... at Massachusetts General Hospital (MGH) one of the ... half rated the training they had received in addiction ... Significant numbers felt unprepared to diagnose or treat such ... response to the findings, recently published online in the ... residents, training in addiction medicine. , "Our residents ...
(Date:5/22/2013)... effect does a father,s depression have on his young son ... intimacy in their marriage, their children benefit, said a University ... their child, they need to be able to attend to ... stage and abilities, and notice whether he is getting frustrated ... said Nancy McElwain, a U of I professor of human ...
(Date:5/22/2013)... A new study suggests that disturbed sleep in ... and greater uncertainly about future success. However, ... appears to have a protective effect. , ... with depressed mood and greater uncertainty about future ... and from teachers were associated with significantly fewer ...
(Date:5/22/2013)... "power plants" that make energy to keep cells alive ... of the drug-resistant forms of cancer source of ... conclusion of a new study published in the journal ... and colleagues explain that doxorubicin and other common forms ... nucleus of cancer cells. Cancer cells divide and multiply ...
Breaking Medicine News(10 mins):Health News:Fish Oil Pills Might Cut Diabetes Risk, Researchers Say 2Health News:Survey points out deficiencies in addictions training for medical residents 2Health News:Survey points out deficiencies in addictions training for medical residents 3Health News:Survey points out deficiencies in addictions training for medical residents 4Health News:Good marriage can buffer effects of dad's depression on young children 2Health News:Parent and teacher support protects teens from sleep problems and depression 2
... Perrigo Company,(Nasdaq: PRGO ; TASE) today announced ... present at the 12th Annual Sidoti Emerging Growth,Institutional ... p.m. (ET) at the,Grand Hyatt Hotel in New ... global healthcare supplier that develops,manufactures and distributes over-the-counter ...
... will be a covered benefit immediately upon its ... members with chronic lymphocytic leukemia, INDIANAPOLIS, March ... effective immediately upon the drug,s,availability, its affiliate health ... coverage for Treanda. Specific benefit plans,may have variable ...
... Natural,Nutrition, Inc. (OTC Bulletin Board: NTNI) ... Finance, Inc., has been,renamed i-Nutrition, Inc. As the ... lending activities of CSI Business Finance have been ... all proceeds from loan payments,received going forward will ...
... Medicine and the Fox Chase Cancer Center have announced ... to join the Temple faculty and train Temple graduate ... share strengths and resources to collaborate on a new ... to those made between other medical schools and cancer ...
... Sharps Compliance Corp.,(OTC Bulletin Board: SCOM) ("Sharps" ... for small quantity generators of,medical waste, announced today ... Senior Vice President of Operations. Mr. Aladwani joins ... developer and,manufacturer of medical devices, where he served ...
... Southwestern Medical Center Patients Will Be the First to Benefit ... ... HOFFMAN ESTATES, Ill., March 24 Siemens Healthcare, (http://www.siemens.com/healthcare ) ... technology at UT Southwestern Medical,Center in Dallas. The facility will ...
Cached Medicine News:Health News:WellPoint's Health Plans to Cover Newly Approved Cancer Treatment 2Health News:Natural Nutrition Renames Former Business Lending Subsidiary i-Nutrition, Inc. 2Health News:Temple and Fox Chase partner on research and education 2Health News:Temple and Fox Chase partner on research and education 3Health News:Temple and Fox Chase partner on research and education 4Health News:Sharps Compliance Corp. Announces Appointment of Al Aladwani as its Senior Vice President of Operations 2Health News:Sharps Compliance Corp. Announces Appointment of Al Aladwani as its Senior Vice President of Operations 3Health News:Siemens Installs First High-Definition PET-CT 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: